2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2018
Physical activity barriers, preferences, and beliefs in childhood cancer patients
Ross WL, Le A, Zheng DJ, Mitchell HR, Rotatori J, Li F, Fahey JT, Ness KK, Kadan-Lottick NS. Physical activity barriers, preferences, and beliefs in childhood cancer patients. Supportive Care In Cancer 2018, 26: 2177-2184. PMID: 29383508, DOI: 10.1007/s00520-017-4041-9.Peer-Reviewed Original ResearchConceptsChildhood cancer patientsCancer patientsTherapy patientsActivity barriersPhysical complaintsPediatric hematology-oncology clinicLow physical activity levelsOff-therapy patientsCancer diagnosisMethodsCross-sectional studyHematology-oncology clinicLong-term complicationsBenefits of exerciseDifferent patient subgroupsPhysical activity levelsPhysical activity barriersLeukemia/lymphomaTherapy statusPatient subgroupsExercise barriersPatientsVs. 12TherapyActivity levelsMost respondents